Abstract
Purpose of Review
The goal of this review is to provide the reader with an updated summary of the cutaneous manifestations of systemic sarcoidosis, with a particular emphasis on the predilection of sarcoidosis for scars, tattoos, and other areas of traumatized skin.
Recent Findings
While the mechanism underlying the propensity for traumatized skin to develop sarcoidosis lesions remains unclear, several theories have been proposed including the idea that cutaneous sarcoidosis represents an exuberant, antigen-driven foreign-body response, as well as the theory that traumatized skin represents an immunocompromised district with altered local immune trafficking and neural signaling.
Summary
In this review, we present two cases in which the development of cutaneous lesions in scars and tattoos was integral to the diagnosis of systemic sarcoidosis. We then review the various cutaneous manifestations of systemic sarcoidosis, the clinical characteristics and differential diagnosis of scar and tattoo sarcoidosis, the proposed mechanism by which traumatized skin is prone to developing sarcoidosis lesions, and current treatments for cutaneous sarcoidosis.
Similar content being viewed by others
Abbreviations
- EN:
-
Erythema nodosum
- TNF:
-
Tumor necrosis factor
References
Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance
Gerke AK, Judson MA, Cozier YC, Culver DA, Koth LL. Disease burden and variability in sarcoidosis. Annals of the American Thoracic Society. 2017;14(Supplement_6):S421–S8. https://doi.org/10.1513/AnnalsATS.201707-564OT.
Iannuzzi MC, Rybicki BA, Teirstein AS. Medical progress: sarcoidosis. New Engl J Med. 2007;357(21):2153–65. https://doi.org/10.1056/Nejmra071714.
English JC, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol. 2001;44(5):725–43. https://doi.org/10.1067/mjd.2001.114596.
•• Wanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med. 2015;36(4):685–702. https://doi.org/10.1016/j.ccm.2015.08.010. A review of the clinical presentation, diagnosis, and management of cutaneous sarcoidosis.
Ruocco E, Gambardella A, Langella GG, Lo Schiavo A, Ruocco V. Cutaneous sarcoidosis: an intriguing model of immune dysregulation. Int J Dermatol. 2015;54(1):1–12. https://doi.org/10.1111/ijd.12566.
Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Resp Med. 2003;97(8):978–82. https://doi.org/10.1016/S0954-6111(03)00127-6.
Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med. 1983;52(208):525–33.
O’Regan A, Berman JS. Sarcoidosis. Ann Intern Med 2012;156(9):ITC5-1, ITC5-2, ITC5-3, ITC5-4, ITC5-, ITC-6, ITC5-7, ITC5-8, ITC5-9, ITC5-10, ITC5-1, ITC5-2, ITC5-3, ITC5-4, ITC5-5; quiz ITC5-6. doi:https://doi.org/10.7326/0003-4819-156-9-201205010-01005, ITC5.
Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist. part II Extracutaneous Disease J Am Acad Dermatol. 2012;66(5):719. e1-10; quiz 29-30–719.e10. https://doi.org/10.1016/j.jaad.2012.02.003.
Marcoval J, Mana J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol. 2011;36(7):739–44. https://doi.org/10.1111/j.1365-2230.2011.04128.x.
Yanardag H, Pamuk ON, Pamuk GE. Lupus pernio in sarcoidosis: clinical features and treatment outcomes of 14 patients. Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases. 2003;9(2):72–6. https://doi.org/10.1097/01.RHU.0000062509.01658.d1.
Mana J, Marcoval J, Graells J, Salazar A, Peyri J, Pujol R. Cutaneous involvement in sarcoidosis—relationship to systemic disease. Arch Dermatol. 1997;133(7):882–8. https://doi.org/10.1001/archderm.133.7.882.
Mangas C, Fernandez-Figueras MT, Fite E, Fernandez-Chico N, Sabat M, Ferrandiz C. Clinical spectrum and histological analysis of 32 cases of specific cutaneous sarcoidosis. J Cutan Pathol. 2006;33(12):772–7. https://doi.org/10.1111/j.1600-0560.2006.00563.x.
Selim A, Ehrsam E, Atassi MB, Khachemoune A. Scar sarcoidosis: a case report and brief review. Cutis. 2006;78(6):418–22.
Zhao S, Wang Q, Cheng B, Zhu XF. Rare scar sarcoidosis: a case report. Experimental and Therapeutic Medicine. 2017;13(4):1535–7. https://doi.org/10.3892/etm.2017.4123.
MacGregor G. Cutaneous sarcoidosis in venepuncture sites. Br Med J. 1973;1(5849):357.
Cecchi R, Giomi A. Scar sarcoidosis following herpes zoster. Journal of the European Academy of Dermatology and Venereology: JEADV. 1999;12(3):280–2.
Veien NK, Stahl D, Brodthagen H. Cutaneous sarcoidosis in Caucasians. J Am Acad Dermatol. 1987;16(3 Pt 1):534–40.
Lubeck G, Epstein E. Complications of tattooing. California Medicine. 1952;76(2):83–5.
• Sepehri M, Carlsen KH, Serup J. Papulo-nodular reactions in black tattoos as markers of sarcoidosis: study of 92 tattoo reactions from a hospital material. Dermatology. 2016;232(6):679–86. https://doi.org/10.1159/000453315. A review of 92 papulo-nodular tattoo reactions demonstrating that almost a third of these reactions were diagnosed with cutaneous or systemic sarcoidosis, particularly when the “rush phenomenon” is present.
Torres LK, Faiz SA. Tattoos and Sarcoidosis. New Engl J Med. 2014;370(23):E34. https://doi.org/10.1056/Nejmicm1215331.
Ayoola R, Mansour W, Gujral J. Tattoo rash. JAMA. 2015;313(17):1747–8. https://doi.org/10.1001/jama.2015.0990.
Simunovic C, Shinohara MM. Complications of decorative tattoos: recognition and management. Am J Clin Dermatol. 2014;15(6):525–36. https://doi.org/10.1007/s40257-014-0100-x.
• Islam PS, Chang C, Selmi C, Generali E, Huntley A, Teuber SS, et al. Medical complications of tattoos: a comprehensive review. Clin Rev Allerg Immu. 2016;50(2):273–86. https://doi.org/10.1007/s12016-016-8532-0. A review of the infectious and non-infectious complications of tattoos including tattoo sarcoidosis.
Morales-Callaghan AM, Aguilar-Bernier M, Martinez-Garcia G, Miranda-Romero A. Sarcoid granuloma on black tattoo. J Am Acad Dermatol. 2006;55(5):S71–S3. https://doi.org/10.1016/j.jaad.2005.12.022.
Val-Bernal JF, Sanchez-Quevedo MC, Corral J, Campos A. Cutaneous sarcoidosis and foreign bodies. An electron probe roentgenographic microanalytic study. Archives of Pathology & Laboratory Medicine. 1995;119(5):471–4.
Walsh NMG, Hanly JG, Tremaine R, Murray S. Cutaneous sarcoidosis and foreign-bodies. Am J Dermatopath. 1993;15(3):203–7. https://doi.org/10.1097/00000372-199306000-00002.
Marcoval J, Mana J, Moreno A, Gallego I, Fortuno Y, Peyri M. Foreign bodies in granulomatous cutaneous lesions of patients with systemic sarcoidosis. Arch Dermatol. 2001;137(4):427–30.
Munro CS, Mitchell DN. The Kveim response—still useful, still a puzzle. Thorax. 1987;42(5):321–31. https://doi.org/10.1136/Thx.42.5.321.
Reich JM. On the nature of sarcoidosis. Eur J Intern Med. 2012;23(2):105–9. https://doi.org/10.1016/j.ejim.2011.09.011.
Hirsch JG, Cohn ZA, Morse SI, Schaedler RW, Siltzbach LE, Ellis JT, et al. Evaluation of the Kveim reaction as a diagnostic test for sarcoidosis. N Engl J Med. 1961;265:827–30. https://doi.org/10.1056/NEJM196110262651703.
Klein JT, Horn TD, Forman JD, Silver RF, Teirstein AS, Moller DR. Selection of oligoclonal V-beta-specific T-cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol. 1995;154(3):1450–60.
Chen ES, Moller DR. Etiologies of sarcoidosis. Clin Rev Allerg Immu. 2015;49(1):6–18. https://doi.org/10.1007/s12016-015-8481-z.
Saidha S, Sotirchos ES, Eckstein C. Etiology of sarcoidosis: does infection play a role? The Yale Journal of Biology and Medicine. 2012;85(1):133–41.
Ruocco V, Brunetti G, Puca RV, Ruocco E. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol. 2009;23(12):1364–73. https://doi.org/10.1111/j.1468-3083.2009.03345.x.
•• Ruocco V, Ruocco E, Piccolo V, Brunetti G, Guerrera LP, Wolf R. The immunocompromised district in dermatology: a unifying pathogenic view of the regional immune dysregulation. Clin Dermatol. 2014;32(5):569–76. https://doi.org/10.1016/j.clindermato1.2014.04.004. A review of the immunocompromised district as a way to describe regions of altered immune regulation in traumatized skin.
Lee R, Saardi KM, Schwartz RA. Lymphedema-related angiogenic tumors and other malignancies. Clin Dermatol. 2014;32(5):616–20. https://doi.org/10.1016/j.clindermato1.2014.04.008.
Ruocco V, Sangiuliano S, Brunetti G, Ruocco E. Beyond zoster: sensory and immune changes in zoster-affected dermatomes: a review. Acta Derm-Venereol. 2012;92(4):378–82. https://doi.org/10.2340/00015555-1284.
Ruocco V, Ruocco E, Ghersetich I, Bianchi B, Lotti T. Isotopic response after herpesvirus infection: an update. J Am Acad Dermatol. 2002;46(1):90–4. https://doi.org/10.1067/mjd.2002.118362.
Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist. Part I Cutaneous Disease J Am Acad Dermatol. 2012;66(5):699. e1-18; quiz 717-8–699.e18. https://doi.org/10.1016/j.jaad.2011.11.965.
Wanat KA, Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol. 2014;15(4):283–97. https://doi.org/10.1007/s40257-014-0079-3.
Green JJ, Lawrence N, Heymann WR. Generalized ulcerative sarcoidosis induced by therapy with the flashlamp-pumped pulsed dye laser. Arch Dermatol. 2001;137(4):507–8.
Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol. 2012;8(1):95–103. https://doi.org/10.1586/eci.11.84.
Droitcourt C, Rybojad M, Porcher R, Juillard C, Cosnes A, Joly P, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014;146(4):1046–54. https://doi.org/10.1378/chest.14-0015.
Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases: Official Journal of WASOG. 2016;32(4):289–95.
•• Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73. https://doi.org/10.1016/j.jaad.2012.10.056. A trial demonstrating the efficacy of infliximab in treating cutaneous sarcoidosis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Informed Consent
Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Autoimmunity
Rights and permissions
About this article
Cite this article
Leverenz, D.L., Henderson, C. & Shah, A. Atypical Cutaneous Presentations of Sarcoidosis: Two Case Reports and Review of the Literature. Curr Allergy Asthma Rep 18, 40 (2018). https://doi.org/10.1007/s11882-018-0794-6
Published:
DOI: https://doi.org/10.1007/s11882-018-0794-6